Source comparison
Origin and Structural Composition of BPC-157 vs LL-37
BPC-157 is a synthetic peptide derived from a naturally occurring protein found in human gastric juice. The parent compound, Body Protection Compound (BPC), was isolated from gastric secretions in the 1990s by Croatian researchers at the University of Zagreb.
This comparison does not assign a generated winner or score.
- BPC-157 is a synthetic peptide derived from a naturally occurring protein found in human gastric juice. The parent compound, Body Protection Compound (BPC), was isolated from gastric secretions in the 1990s by Croatian researchers at the University of Zagreb. The synthetic version—BPC-157—is a stable 15-amino-acid fragment (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) designed to retain the cytoprotective and regenerative properties of the full-length protein while remaining stable at room temperature and resistant to enzymatic degradation in vivo. BPC-157 does not occur naturally in this exact sequence—it is an engineered analogue optimized for research stability.
- LL-37, by contrast, is the biologically active form of the human cathelicidin antimicrobial peptide hCAP-18. hCAP-18 is synthesized as an inactive precursor in neutrophils, epithelial cells, and other immune tissues. Upon microbial challenge or tissue injury, the enzyme proteinase-3 cleaves hCAP-18 to release the active 37-amino-acid peptide LL-37—so named because it begins with two leucine residues. This peptide is part of the innate immune system's first-line defense and is constitutively expressed in mucosal tissues, sweat, saliva, and airway secretions. LL-37 research typically uses synthetic versions identical to the endogenous sequence, ensuring functional equivalence to the peptide expressed during infection or inflammation.
- The structural difference between BPC-157 and LL-37 dictates their behavior in experimental models. BPC-157's proline-rich sequence confers conformational flexibility, allowing it to interact with multiple growth factor receptors and extracellular matrix proteins simultaneously. LL-37's amphipathic alpha-helical structure enables it to insert into microbial membranes, disrupting lipid bilayers and causing cell lysis—a mechanism entirely absent in BPC-157. These structural distinctions mean the two peptides cannot substitute for one another in protocols designed around their unique mechanisms.